2016 Fiscal Year Final Research Report
The combination therapy of novel oncolytic virus with molecular targeted drug
| Project/Area Number |
26462182
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
DATE Isao 岡山大学, 医歯薬学総合研究科, 教授 (70236785)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | Oncolytic virus / stem cell / antiangiogenesis / glioma / molecular targeted drug / antiinvasion |
|---|
| Outline of Final Research Achievements |
Oncolytic viral (OV) therapy has been considered as a promising treatment modality for brain tumors. Previously a novel HSV-1 derived OV, 34.5ENVE (viral ICP34.5 Expressed by Nestin promotor and Vstat120 Expressing), was reported to have a potent antitumor effect. Here, we investigated the therapeutic efficacy of 34.5ENVE and cilengitide, an integrin inhibitor, or, bevacizumab, an VEGF antibody combination therapy for malignant glioma. Before the experiment of the combination with 34.5ENVE and targeted drug we evaluated the combination therapy with a first generation OV armed with the antiangiogenic gene Vstat120 (RAMBO). In the scratch wound assay, RAMBO CM significantly reduced both the number of migrating cells and the rate of migration. Furthermore, the number and the rate of migrating cells induced by bevacizumab treatment was reduced by RAMBO CM. These results indicate that targeted drug enhanced OV therapy for malignant glioma.
|
| Free Research Field |
医歯薬学、外科系臨床医学、脳神経外科学
|
